News


All News

Two of the hottest controversies in today’s dermatologic drug therapy involve medical concerns surrounding finasteride (Propecia, Merck) and Zostavax (zoster vaccine live, Merck), said Stephen E. Wolverton, M.D., at the 2012 American Academy of Dermatology Summer Academy Meeting.

From improving patient payments to fully harnessing the power of social media networks, the Business of Dermatology provides how-to guides for streamlining your medical practice operations. This special section from the August issue of Dermatology Times magazine also gives clinicians a complete picture of how to integrate an electronic health records system while avoiding potential pitfalls.

Striking a balance : How do dermatologists walk the fine line between contributing to industry research & providing impartial care? National report - Physicians’ relationships with industry have long been an ethical tug of war, yet they remain commonplace. Battling Back : Vismodegib proves effective in the fight against basal cell nevus syndrome Clinical Dermatology : Exploring the obstacles, opportunities associated with today’s vaccines Cosmetic Dermatology : Best shaving practices to share with your male patients Cutaneous Oncology : Why educating patients about sunscreens is easier than ever before Special Report : Women's Dermatologic conditions

Achieving meaningful use and avoiding common mistakes in implementing an electronic health record (EHR) system require careful planning and learning from others' experiences, said Michael Doyle, chairman of Medsphere Systems Corporation, at the 70th annual meeting of the American Academy of Dermatology.

Merkel cell carcinoma (MCC) is a neuroendocrine tumor of the skin that is very aggressive and potentially lethal. As such, treatment approaches and disease management should also be aggressive and appropriately address the patient's disease and symptoms. Treatment choices depend on the stage of the tumor, however, as well as the general health of the affected patient.

Physicians' relationships with industry have long been an ethical tug of war, yet they remain commonplace. And with government's increasing focus on transparency - augmented with the U.S. Supreme Court upholding of the Patient Protection and Affordable Care Act - consulting, research and other relationships with pharmaceutical and medical device companies will become even more visible.

Recently, Northwestern University Feinberg School of Medicine surveyed their third- and fourth-year residents and found that even though it is not on the official curriculum, the residents are learning defensive medicine. Whether it's an attending mentioning that a particular biopsy isn't necessary or deciding not to offer a patient a particular medication because it of a potential lawsuit, the residents are seeing defensive medicine in practice.

Hyperhidrosis, or excessive sweating, can be a physically and emotionally distressing condition. In 2004, the United States prevalence rates were estimated to be 1.4 percent (more than 4 million people; Strutton DR, Kowalski JW, Glasser DA, et al. J Am Acad Dermatol. 2004;51(2):241-248).

The hedgehog inhibitor drug vismodegib (Erivedge, Genentech/Roche), approved in January to treat advanced and metastatic basal cell carcinoma, has demonstrated potent clinical activity when used in patients with basal cell nevus syndrome, according to a study published recently in the New England Journal of Medicine.